ABIONYX Pharma: 2025 Half-Year Financial Results

About this update from Abionyx Pharma Sa

[{"type":"text","content":"TOULOUSE, France & FULLERTON, Calif., September 25, 2025--(BUSINESS WIRE)--Regulatory News:","length":95,"tagName":"p"},{"type":"text","content":"ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant apoA-1, today announces its financial results for the first half of 2025.","length":273,"tagName":"p"},{"type":"text","content":"Main changes in the consolidated financial statements","length":53,"tagName":"p"},{"type":"text","content":"As mentioned in the publication of the half-yearly revenue figures on August 28, the activity dedicated to the discovery and development of innovative therapies, particularly in sepsis and the rare diseases LCAT deficiency and Norum disease, aimed at improving or even saving patients' lives, has not yet generated any revenue during this half-year. ABIONYX Pharma continues to provide its bioproduct free of charge in the context of compassionate use authorization (CUA) requests for Norum disease.","length":503,"tagName":"p"},{"type":"text","content":"The ABIONYX Pharma group recorded consolidated half-year revenue of €2.1 million in the first half of 2025, which relates solely to its subsidiary IRIS Pharma's contract research organization (CRO) activity in ophthalmology. The group did not commission any studies from IRIS Pharma during this half-year period. The activity of the IRIS Pharma subsidiary is expected to remain stable over the year despite an unfavorable economic environment in the global research sector.","length":477,"tagName":"p"},{"type":"text","content":"As of June 30, 2025, research and development expenses amounted to €692K, compared to €861K as of June 30, 2024. Administrative and commercial expenses amounted to €1,876K as of June 30, 2025, compared to €1,579K as of June 30, 2024.","length":233,"tagName":"p"},{"type":"text","content":"After taking these expenses into account, operating income went from a loss of €2,124K as of June 30, 2024, to a loss of €2,330K as of June 30, 2025. Financial income was positive at €32K as of June 30, 2025, compared to a profit of €36K in the first half of 2024. The financial result is mainly related to financial income from the investment of cash surpluses. The net loss amounted to €2,306K at Jun...

More updates from Abionyx Pharma Sa